Plain-English translation of NCT06562192 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new radioactive medication called to treat advanced cancers that have not responded to standard chemotherapy, immunotherapy, or targeted therapy. The treatment works by delivering radiation directly to cancer cells. Researchers are first figuring out the safest and most effective dose, then testing how well it works and monitoring how patients tolerate it.
Many patients with advanced pancreatic, lung, breast, and colorectal cancers run out of treatment options when their cancer stops responding to existing therapies. This medication offers a new approach by using radioactive particles to target cancer cells, potentially giving patients another option when standard treatments fail.
You likely qualify if…
You likely don't qualify if…
You will first undergo a diagnostic imaging scan to confirm your cancer responds to the medication. If eligible, you will then receive the radioactive treatment as an infusion. The study has two phases: in the first phase, researchers test different doses to find the best one; in the second phase, more patients receive the recommended dose while researchers monitor safety and effectiveness. You will have regular follow-up visits and imaging scans for up to 3 years after treatment to track your progress and watch for any side effects.
AI-generated summary from trial data · Aug 4, 2026 · Not medical advice
United States